Central European Time

SOPHiA GENETICS Reports First Quarter 2024 Results

Retrieved on: 
Martedì, Maggio 7, 2024
Liquid biopsy, Table, Mayo Clinic, Cancer, NHS, Health equity, COVID, Average cost, Book of Wisdom, Breast cancer, FY, GENETICS, Traction, Sophia Genetics, Research, Forecasting, Growth, SOPHIA, NGS, Public expenditure, Algorithm, Patient, MSK, Eastern Time Zone, Acquisition, Medicine, Pension, COVID-19, AstraZeneca, Constant, Central European Time, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • BOSTON and ROLLE, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2024.
  • SOPHiA GENETICS will host a conference call and live webcast to discuss the first quarter 2024 results on Tuesday, May 7, 2024, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time.
  • The call will be webcast live on the SOPHiA GENETICS Investor Relations website, ir.sophiagenetics.com.
  • Additionally, an audio replay of the conference call will be available on the SOPHiA GENETICS website after its completion.

ANNUAL GENERAL MEETING OF THE SHAREHOLDERS OF THE COMPANY

Retrieved on: 
Venerdì, Maggio 3, 2024
USD, Remuneration, Mass meeting, PDF, Proxy, Exercise, Documentation, Bank statement, Central European Time, Disclosure, Audit

To receive the reports of the approved statutory auditor of the Company on the statutory and the consolidated financial statements of the Company for financial year ended December 31, 2023.

Key Points: 
  • To receive the reports of the approved statutory auditor of the Company on the statutory and the consolidated financial statements of the Company for financial year ended December 31, 2023.
  • To appoint MOORE Audit S.A. as approved statutory auditor of the Company, to hold office until the conclusion of the next Annual General Meeting.
  • To authorize the Board of Directors of the Company to determine the remuneration of the approved statutory auditor of the Company.
  • A copy of the documentation related to the General Meeting is available at the registered office of the Company.

STMicroelectronics Reports 2024 First Quarter Financial Results

Retrieved on: 
Giovedì, Aprile 25, 2024
Appendix, Public, Climate change, Tsunami, Pandemic, Weather, Nature, Risk, Annual report, Earthquake, Security (finance), Epidemic, Euro, Carbon, Public expenditure, Privacy, Legislation, Intellectual property, Share repurchase, GAAP, Central European Time, Cryptocurrency

Net Capex (non-U.S. GAAP)1 was $967 million in the first quarter compared to $1.09 billion in the year-ago quarter.

Key Points: 
  • Net Capex (non-U.S. GAAP)1 was $967 million in the first quarter compared to $1.09 billion in the year-ago quarter.
  • Free cash flow (non-U.S. GAAP)1 was negative at $134 million in the first quarter, compared to positive $206 million in the year-ago quarter.
  • Inventory at the end of the first quarter was $2.69 billion, compared to $2.70 billion in the previous quarter and $2.87 billion in the year-ago quarter.
  • Days sales of inventory at quarter-end was 122 days compared to 104 days in the previous quarter and 122 days in the year-ago quarter.

Esker Q1 2024 Sales Activity

Retrieved on: 
Martedì, Aprile 16, 2024
Software, Payments, Finance, Data Management, Professional Services, Technology, Security, Business, History, Investment, Treasury, Nature, ARR, Growth, Acceleration, Central European Time

Esker Q1 2024 consolidated sales revenue amounted to 47.7 million euros, a 12% increase over Q1 2023 based on current as well as constant exchange rates.

Key Points: 
  • Esker Q1 2024 consolidated sales revenue amounted to 47.7 million euros, a 12% increase over Q1 2023 based on current as well as constant exchange rates.
  • Sales activity in Europe (excluding France) was down 18% compared to Q1 2023 due to a particularly demanding base effect (+191% in Q1 2023).
  • Against a backdrop of exceptional bookings in Q1 2024, Esker expects its revenue growth to be between 12-14%, excluding acquisitions and currency effects, for 2024.
  • An English webcast with Jean-Michel Bérard (Esker CEO) and Emmanuel Olivier (Esker COO) will take place April 16, 2024, at 6:30 p.m. Central European Time.

Aperam publishes Convening Notice for Annual General Meeting of shareholders

Retrieved on: 
Mercoledì, Aprile 10, 2024
Central European Time, Mass meeting, Aperam, Security (finance)

Luxembourg March 29, 2024 (07:00 CET) - Aperam announces the publication of the convening notice for its Annual General Meeting of shareholders (“the General Meeting”), which will be held on Tuesday 30 April 2024 at 11:00 hours at Luxembourg time at 24-26, boulevard d'Avranches, L-1160 Luxembourg, Grand-Duchy of Luxembourg.

Key Points: 
  • Luxembourg March 29, 2024 (07:00 CET) - Aperam announces the publication of the convening notice for its Annual General Meeting of shareholders (“the General Meeting”), which will be held on Tuesday 30 April 2024 at 11:00 hours at Luxembourg time at 24-26, boulevard d'Avranches, L-1160 Luxembourg, Grand-Duchy of Luxembourg.
  • The Aperam shareholders entitled to vote at the General Meeting will be those who are shareholders on the record date of 16 April 2024 at midnight (24:00 hours) Central European Time.

STMicroelectronics Announces Timing for First Quarter 2024 Earnings Release and Conference Call

Retrieved on: 
Giovedì, Aprile 4, 2024
Central European Time, Electronics, STM

Geneva – April 4, 2024 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, announced that it will release first quarter 2024 earnings before the opening of trading on the European Stock Exchanges on April 25, 2024.

Key Points: 
  • Geneva – April 4, 2024 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, announced that it will release first quarter 2024 earnings before the opening of trading on the European Stock Exchanges on April 25, 2024.
  • STMicroelectronics will conduct a conference call with analysts, investors and reporters to discuss its first quarter 2024 financial results and current business outlook on April 25, 2024 at 9:30 a.m. Central European Time (CET) / 3:30 a.m. U.S. Eastern Time (ET).
  • A live webcast (listen-only mode) of the conference call will be accessible at ST’s website, http://investors.st.com , and will be available for replay until May 10, 2024.

Fortuna to present at the Gold Forum Europe 2024 in Zürich, Switzerland

Retrieved on: 
Lunedì, Marzo 25, 2024
FSM, Central European Time, TSX, FVI

VANCOUVER, British Columbia, March 25, 2024 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) is pleased to announce that it will be attending Gold Forum Europe 2024 , which is being held at the Park Hyatt in Zürich, Switzerland, from April 8 to 10, 2024.

Key Points: 
  • VANCOUVER, British Columbia, March 25, 2024 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) is pleased to announce that it will be attending Gold Forum Europe 2024 , which is being held at the Park Hyatt in Zürich, Switzerland, from April 8 to 10, 2024.
  • Jorge A. Ganoza, President, Chief Executive Officer, and co-founder of Fortuna, will be presenting on Tuesday, April 9 at 2:30 p.m. Central European Time in Ballroom 3.

Coeur to Present at Gold Forum Europe

Retrieved on: 
Giovedì, Aprile 4, 2024
Natural Resources, Other Natural Resources, Mining, Minerals, CDE, Senior, Central European Time

Coeur Mining, Inc. (“Coeur” or the “Company”) (NYSE: CDE) announced today that Senior Vice President and Chief Financial Officer Thomas S. Whelan will present at Gold Forum Europe in Zurich, Switzerland on Wednesday, April 10, 2024 at 1:10 p.m. Central European Time.

Key Points: 
  • Coeur Mining, Inc. (“Coeur” or the “Company”) (NYSE: CDE) announced today that Senior Vice President and Chief Financial Officer Thomas S. Whelan will present at Gold Forum Europe in Zurich, Switzerland on Wednesday, April 10, 2024 at 1:10 p.m. Central European Time.
  • Gold Forum Europe is an invitation-only investment conference.
  • Presentation materials will be made available on the Company’s website at www.coeur.com .

Esker 2023 Annual Results

Retrieved on: 
Mercoledì, Marzo 27, 2024
Professional Services, Payments, Data Management, Business, Security, Technology, Finance, Automation, Central European Time, Software as a service, Growth, ARR, FY, Acceleration, Travel, Policy, Acquisition, Market Dojo, Bank statement, Esker, Publication, Investment, Treasury, Marketing, Pharmaceutical industry

Esker 2023 sales revenue amounted to 178.6 million euros, a 12% increase over 2022 (14% based on constant exchange rates).

Key Points: 
  • Esker 2023 sales revenue amounted to 178.6 million euros, a 12% increase over 2022 (14% based on constant exchange rates).
  • The annual recurring value (ARR) of new contracts signed during 2023 increased by 23% based on constant exchange rates compared to 2022.
  • As announced at publication of the Q3 2023 sales results, the increase in sales costs linked to the acceleration in bookings impacts 2023 operating income for 3.5 million euros, or 1.9% of sales.
  • As anticipated at the time of the half-year and Q3 2023 results, Esker’s operating profitability for 2023 fell by 3.5 points to 10% of sales revenue.

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

Retrieved on: 
Venerdì, Marzo 22, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, SMMT, Intraparenchymal hemorrhage, Sun, EGFR, Central European Time, Metastasis, ELCC, Progression-free survival, Anaplastic lymphoma kinase, Constipation, Brain, Drug, HKEX, Safety, Anemia, Phase, Summit, TKI, Time in Europe, PFS, ALK, Pharmaceutical industry

The first poster, “Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases” includes data from patients with asymptomatic brain metastases at baseline.

Key Points: 
  • The first poster, “Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases” includes data from patients with asymptomatic brain metastases at baseline.
  • This analysis consisted of the 35 patients with advanced or metastatic NSCLC who had asymptomatic brain metastases at baseline; 28 patients were treated with ivonescimab plus chemotherapy in AK112-201, and seven patients were treated with monotherapy ivonescimab in AK112-202.
  • Patients across both cohorts experienced an intracranial response rate of 34%, and eight patients (23%) experienced a complete response by RANO criteria.
  • The most frequent TEAEs were anemia and decreased neutrophil counts in squamous patients and anemia and constipation in non-squamous patients.